Xtandi and Bosulif Are Expected to Boost Pfizer’s Revenue Growth

In the first nine months of this year, Pfizer’s (PFE) Xtandi alliance revenue grew ~21% YoY (year-over-year) to $510.0 million. Astellas Pharma and Pfizer jointly commercialize Xtandi in US markets, while Astellas Pharma manufactures and commercializes the drug internationally. In the third quarter, Xtandi alliance revenue grew ~20% YoY to $180.0 million. Xtandi is used to treat prostate cancer that cannot be diminished through surgical or testosterone therapy.

In the first nine months of this year, Pfizer’s Bosulif sales grew ~27% YoY to $206.0 million from $163.0 million. US Bosulif sales grew ~24% to $136.0 million from $110.0 million, and international Bosulif sales grew ~32% YoY to $71.0 million.

In the third quarter, Bosulif’s net revenue grew ~20% YoY to $69.0 million. US and international Bosulif revenue grew ~13% and ~33% YoY to $43.0 million and $26.0 million, respectively.

Bosulif is used to treat Philadelphia-chromosome-positive chronic myelogenous leukemia. It competes with Takeda Pharmaceutical’s (TKPYY) Iclusig, Novartis’s (NVS) Tasigna, and Bristol-Myers Squibb’s (BMY) Sprycel.